Lisa Anson, CEO, Redx Pharma 00:00:00

Share On Facebook Share On Twitter

Anson discusses the company's performance in 2023 and outlined its plans for 2024. She highlights the successful launch of a Phase 2 program for lead asset Zelasudil, aimed at treating idiopathic pulmonary fibrosis, a challenging lung condition.

Recent Videos